维普期刊资源整合服务平台（V6.5）

56篇 您的检索式：作者名="Lohrisch"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	An overview of HER2显示文摘	Piccart M	2001	Semin Oncol2001，28，618：	1
2	An overview of HER2显示文摘	Lohrisch C Piccart M	2001	Semin Oncol2001，28，618：	1
3	HER2Jneu as a predictive factor in breast cancer显示文摘	Lohrisch C Piccart M	2001	Clin Breast Cancer:2001，2，2：	1
4	Mature results of a randomized phase Ⅱ multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer显示文摘	Paridaens R Dirix L Lohrisch C	2003	Ann Oncol2003，14，9：	1
5	HER-2/neu as a predictive factor in breast cancer 显示文摘	Lohrisch C Piccart M	2001	Clin Breast Cancar2001，2，2：	1
6	Mature results of a randomized phase II postmenopausal women with metastatic breast cancer 显示文摘	Atalay G Dirix L Lohrisch C	2003	Ann Oncol2003，，9：	1
7	The Predictive Value of HER2 in Breast Cancer显示文摘	Piccart M Lohrisch C Di Leo A	2001	Oncology2001，612，：	1
8	Mature results of a randomized phase Ⅱ multicenter study of exemestane versus tamoxifeu as first-line hormone therapy for postmeuopausal women with metastatic breast cancer 显示文摘	PARIDAENS R DIRIX L LOHRISCH C	2003	Ann Oncol2003，14，9：	1
9	An overview of HER2显示文摘	Lohrisch C Piccart M	2001	Semin Oncol2001，28，618：	1
10	HER -2/neu as a predictive factor in breast cancer 显示文摘	Lohrisch C Piccart M	2001	Clin Breast Cancer2001，2，2：	1
11	Mature results of a randomized phase Ⅱ multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer显示文摘	Paridaens R Dirix L Lohrisch C	2003	Ann Oncol2003，14，9：	1
12	An overview of HER 2显示文摘	Lohrisch C Piccart M	2001	Se- min Oncol2001，28，618：	1
13	Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer 显示文摘	LOHRISCH C PALTIEL C GELMON K	2006	J Clin Oncol2006，24，30：	1
14	Mature results of a randomized phase Ⅱ multicenter study of exemestane versus tamoxifen as first - line hormone therapy for postmenopausal women with metastatic breast cancer显示文摘	Paridaens R Dirix L Lohrisch	2003	Ann Oncol2003，14，9：	1
15	Mature results of a randomized phase Ⅲ multicenter study of exemestane versus tamoxifen as first - line hormone therapy for postmenopausal women with metastatic breast cancer显示文摘	Paridaens R Dirix L Lohrisch C	2003	Ann Oncol2003，14，9：	1
16	Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first - line hormone therapy for postmenopausal women with metastatic breast cancer 显示文摘	Paridaens R Dirix L Lohrisch E	2003	Ann Oncol2003，14，9：	1
17	Mature results of a randomized phase Ⅱ multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer显示文摘	Paridaens R Dirix L Lohrisch C	2003	Ann Oncol2003，14，9：	1
18	Mature results of a randomized phase Ⅱ multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer 显示文摘	Paridaens R Dirix L Lohrisch C	2003	Ann Oncol2003，14，9：	1
19	Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer显示文摘	Paridaens R Dirix L Lohrisch C	2003	Ann Oncol2003，14，9：	1
20	The predictive value of HER2 in breast cancer显示文摘	Piccart M Lohrisch C Di Leo	2001	Oncology2001，61，：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示